R&D expense · 2017–2025
Bridgebio Pharma R&D expense
$452M−10.8% · FY2025
Bridgebio Pharma (BBIO) reported $452M in R&D expense for fiscal 2025, −10.8% year on year.
| Fiscal year | R&D expense | Change | Filing |
|---|---|---|---|
| FY20252025-12-31 | $452M | −10.8% | Open → |
| FY20242024-12-31 | $506M | +11.1% | Open → |
| FY20232023-12-31 | $456M | +14.1% | Open → |
| FY20222022-12-31 | $399M | −11.4% | Open → |
| FY20212021-12-31 | $451M | +33.8% | Open → |
| FY20202020-12-31 | $337M | +60.5% | Open → |
| FY20192019-12-31 | $210M | +49.9% | Open → |
| FY20182018-12-31 | $140M | +358.4% | Open → |
| FY20172017-12-31 | $30.6M | — | Open → |
R&D expense — Research and development expense is what the company charged to R&D in the income statement for the year. Most companies report no R&D at all — the line is absent rather than zero — so this ranking covers the roughly 40% of filers that do.
Every row links to its own SEC filing · Fiscal year 2025 · Data as of September 25, 2026 · 2017–2025 compound annual growth +40.0%
R&D expense at companies of similar size
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Bridgebio Pharma R&D expense |url=https://companiesranked.com/en/company/bridgebio-pharma/research-and-development-expense |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Bridgebio Pharma R&D expense. CompaniesRanked. https://companiesranked.com/en/company/bridgebio-pharma/research-and-development-expenseBibTeX
@misc{companiesranked-en-company-bridgebio-pharma-research-and-development-expense-2026,
author = {{CompaniesRanked}},
title = {{Bridgebio Pharma R\&D expense}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/bridgebio-pharma/research-and-development-expense}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001743881-26-000009 · February 24, 2026
{{cite web |title=Bridgebio Pharma R&D expense — 10-K (0001743881-26-000009) |url=https://www.sec.gov/Archives/edgar/data/1743881/000174388126000009/bbio-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-24}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.